NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Feb 27, 2024 | Press Releases

CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

Jan 31, 2024 | Press Releases

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer

Dec 20, 2023 | Press Releases

CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Reports Third Quarter 2023 Financial Results

Nov 20, 2023 | Press Releases

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Announces CareFirst BCBS Policy Coverage

Nov 15, 2023 | Press Releases

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in...

NeurAxis Secures $3 Million Financing

Nov 14, 2023 | Press Releases

CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in...